|
Arix Bioscience PLC - London-based venture capital investor in biotech firms - Notes that portfolio company Harpoon Therapeutics Inc discontinued its phase 1/2 dose-escalation study for HPN424, a treatment for advanced prostate cancer, following a thorough analysis of its HPN424 data. The decision will allow Harpoon to concentrate on HNP328, a treatment in development for tumours associated with delta-like ligand 3 expression, and on HPN 217 for BCMA, an important therapeutic target in the treatment of multiple myeloma.
Current stock price: 118.00, down 0.4% on Tuesday
12-month change: down 39%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
